Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
CHUGAI PHARMACEUTICAL CO., LTD- founded in 1925- is committed to providing high-quality healthcare and improving people’s health, well-being and quality of life. With global horizon, Chugai is increasingly focusing on Research and Development (R＆D). Our mission today and tomorrow is to create exceptional added value in healthcare, and proceed to be a leading international health care company.
To service Taiwan, Chugai set up a Taipei branch company in 1988, and merged with HUEY MAW TRADING CO., LTD. to become CHUNG HUEY PHARMACEUTICAL CO., LTD. in 1991. In October 2001, the company officially changed the name to CHUGAI PHARMA TAIWAN and reran the business for marketing hospital-based products. Most of the pharmaceutical products import from Japan headquarters directly and part of them are toll manufacture locally; furthermore, CHUGAI PHARMA TAIWAN CO., LTD and SHUN HWA CO., LTD are responsible for marketing business to remain constant: to improving patient care.
Major products
GRANOCYTE (Recombinant Human Granocyte Colony-Stimulating Factor Preparation)
SIGMART (Anti Angina Pectoris Agent)
Company Name: Chugai Pharma Taiwan Ltd.
Address: 3Fl., No. 73, ZhouZi Street, Neihu District,Taipei 10493, Taiwan
Telephone: (02)2658-8800
Fax: (02)2658-8852
E-Mail: cpt@chugai.com.tw
Website: www.chugai-pharm.co.jp
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
See our Cookie Privacy Policy Here
